ONCO - Onconetix, Inc. Revenue Growth YoY (Last 12 Months)

Onconetix, Inc. (ONCO) maintains a strong reputation in prostate therapy and oncology. A chart of the current year-over-year (TTM) revenue growth rate is available in the GURU.Markets system, where the value -51.40 reflects the current figure. Growth is driven by the launch of Entadfi and niche urological markets, while the company's strategic image is currently based on innovation and the clinical trust of physicians.
Onconetix, Inc. - analytical breakdowns and key metrics (ONCO)

This metric measures the percentage change in revenue over the last twelve months relative to the same period last year, reflecting the actual scaling speed of the business. By analyzing this TTM year-over-year sales growth chart, an investor assesses the effectiveness of implementing Onconetix, Inc. (ONCO) automated diagnostic systems, where growth in this metric confirms the commercial success of robotic biosample processing and billing digitalization.